Identification of Fangjihuangqi Decoction as a late-stage autophagy inhibitor with an adjuvant anti-tumor effect against non-small cell lung cancer
-
Published:2023-06-07
Issue:1
Volume:18
Page:
-
ISSN:1749-8546
-
Container-title:Chinese Medicine
-
language:en
-
Short-container-title:Chin Med
Author:
Chen Qiugu,Liao Yuan,Liu Yujiao,Song Yue,Jiang Junbo,zhang Zhen,Li Anqi,zheng Mengyi,Chen Xiaoyi,Zhao Tingxiu,Gu Jiangyong,Tan Yuhui,Liu Xiaoyi,Jiang Yanjun,Wang Kun,Yi Hua,Xiao Jianyong,Hu Shan
Abstract
Abstract
Background
Clinically, although chemotherapy is one of the most commonly used methods of treating tumors, chemotherapeutic drugs can induce autophagic flux and increase tumor cell resistance, leading to drug tolerance. Therefore, theoretically, inhibiting autophagy may improve the efficacy of chemotherapy. The discovery of autophagy regulators and their potential application as adjuvant anti-cancer drugs is of substantial importance. In this study, we clarified that Fangjihuangqi Decoction (FJHQ, traditional Chinese medicine) is an autophagy inhibitor, which can synergistically enhance the effect of cisplatin and paclitaxel on non-small cell lung cancer (NSCLC) cells.
Methods
We observed the changes of autophagy level in NSCLC cells under the effect of FJHQ, and verified the level of the autophagy marker protein and cathepsin. Apoptosis was detected after the combination of FJHQ with cisplatin or paclitaxel, and NAC (ROS scavenger) was further used to verify the activation of ROS-MAPK pathway by FJHQ.
Results
We observed that FJHQ induced autophagosomes in NSCLC cells and increased the levels of P62 and LC3-II protein expression in a concentration- and time-gradient-dependent manner, indicating that autophagic flux was inhibited. Co-localization experiments further showed that while FJHQ did not inhibit autophagosome and lysosome fusion, it affected the maturation of cathepsin and thus inhibited the autophagic pathway. Finally, we found that the combination of FJHQ with cisplatin or paclitaxel increased the apoptosis rate of NSCLC cells, due to increased ROS accumulation and further activation of the ROS-MAPK pathway. This synergistic effect could be reversed by NAC.
Conclusion
Collectively, these results demonstrate that FJHQ is a novel late-stage autophagy inhibitor that can amplify the anti-tumor effect of cisplatin and paclitaxel against NSCLC cells.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Guangdong Province
the Science and Technology Plan Project of Guangzhou of China
the Guangdong Provincial Bureau of Traditional Chinese Medicine Research Foundation
the Guangdong Medical Science and Technology Research Foundation
the National Undergraduate Training Programs for Innovation and Entrepreneurship
Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,Pharmacology
Reference43 articles.
1. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc. 2019;94(8):1623–40.
2. Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer[J]. Expert Rev Anticancer Ther. 2018;18(1):63–70.
3. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer[J]. Nat Med. 2021;27(8):1345–56.
4. Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer[J]. J Hematol Oncol. 2020;13(1):58.
5. Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms[J]. Autophagy. 2018;14(2):207–15.